Name: Orelabrutinib
Brand: Selleck Chemicals
SKU: S9600
Availability: InStock
Rating: 5 (1 reviews)

Jump to

Quality Control

Batch: S960001 DMSO]86 mg/mL]false]Ethanol]10 mg/mL]false]Water]Insoluble]false Purity: 99.95%

Cited in Nature Medicine for its top-tier quality
COA
NMR
SDS/MSDS
Datasheet

99.95

Related Targets	EGFR VEGFR JAK FGFR PDGFR Src HIF FLT3 HER2 FLT
Other BTK Inhibitors	Catadegbrutinib (BGB-16673) Spebrutinib (AVL-292) tirabrutinib(ONO-4059) hydrochloride LFM-A13 CGI1746 Evobrutinib BMS-935177 CNX-774 Branebrutinib (BMS-986195) Fenebrutinib (GDC-0853)

Solubility

In vitro
Batch:

DMSO : 86 mg/mL (201.17 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 10 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	4.300mg/ml (10.06mM)	Taking the 1 mL working solution as an example, add 50 μL of 86 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.710mg/ml (1.66mM)	Taking the 1 mL working solution as an example, add 50 μL of 14.2 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	427.49	Formula	C₂₆H₂₅N₃O₃	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	1655504-04-3	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	ICP-022			SMILES	C=CC(=O)N1CCC(CC1)C2=NC(=C(C=C2)C(=O)N)C3=CC=C(C=C3)OC4=CC=CC=C4

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	BTK
In vitro	Orelabrutinib potently inhibits BTK enzymatic activity with an IC50 value of 1.6 nM. In KINOMEscan assay conducted in parallel at 1 μM against a panel of 456 kinases, this compound only targets BTK with > 90% inhibition while ibrutinib inhibits additional many other kinases including EGFR, TEC and BMX, demonstrating its superior kinase selectivity.
In vivo	Orelabrutinib has a favorable PK profile with an ideal T1/2 (~1.5-4 h) and good oral bioavailability (~20-80%) as well as prolonged BTK target occupancy in preclinical PK/PD studies. The superior selectivity of this compound translates into improved safety profile and large safety window in the GLP toxicology studies in rats and dogs.
References	[1] https://doi.org/10.1182/blood-2019-123331 [2] https://cancerres.aacrjournals.org/content/80/16_Supplement/CT132.short

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-08-25)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07784101	NOT_YET_RECRUITING	Relapsed or Refractory Mantle Cell Lymphoma (MCL)	Beijing InnoCare Pharma Tech Co., Ltd.	2026-10	PHASE3
NCT06363994	RECRUITING	Mantle Cell Lymphoma	InnoCare Pharma Inc.	2024-05-29	PHASE3
NCT07377578	RECRUITING	Mantle Cell Lymphoma	Guangzhou Lupeng Pharmaceutical Company LTD.	2026-02-05	PHASE3
NCT06378138	RECRUITING	Hematologic Malignancies	Beijing InnoCare Pharma Tech Co., Ltd.	2024-05-15	PHASE2; PHASE3
NCT07719855	NOT_YET_RECRUITING	Follicular Lymphoma ( FL)	Ruijin Hospital	2026-07	PHASE3
NCT07299019	RECRUITING	Secondary Progressive Multiple Sclerosis	Zenas BioPharma (USA), LLC	2026-03-23	PHASE3

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Orelabrutinib BTK inhibitor

Chemical Structure

Molecular Weight: 427.49